New class of small molecule therapeutics introduced

Beyond Biotech - the podcast from Labiotech

Το περιεχόμενο παρέχεται από το Labiotech. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Labiotech ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

6M ago 26:35

MP3•Αρχική οθόνη επεισοδίου

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

96 επεισόδια

#News #Tech News #Labiotech